Posted by Michael Wonder on 31 Aug 2016
Schedule of Pharmaceutical Benefits - 1 September 2016 update
1 September 2016 - The 1 September 2016 issue of the Schedule of Pharmaceutical Benefits sees a number of new and revised listings.
The new/revised listings are:
- Bevacizumab (Avastin) - new indication
- Exenatide (Bydureon) - new formulation
- Linagliptin (Trajenta) - new indication
- Linagliptin with metformin hydrochloride (Trajentamet) - new indication
- Vildagliptin (Galvus) - new indication
- Vildagliptin with metformin hydrochloride (Galvumet) - new indication
